Third-Line Treatment Options for Metastatic Colorectal Cancer - Episode 4

Perspectives on the SUNLIGHT Trial: Study Design and Outcomes

November 28, 2024

Marwan G. Fakih, MD, City of Hope, Nilo Azad, MD

Panelists discuss their perspectives on the SUNLIGHT trial and how its active-arm comparator design, compared with placebo-controlled trials like FRESCO-2 and CORRECT, influences their treatment approach, while also exploring how specific efficacy outcomes impact their decision-making in third-line metastatic colorectal cancer.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Navigating mCRC: Treatment Options in the Third-Line Setting

EP. 2: Nuances With Defining “Refractory” mCRC in the Third-Line Setting

EP. 3: Treatment Sequencing in mCRC: Balancing Expert Perspectives and Shared Decision-Making With Patients

Now Viewing

EP. 4: Perspectives on the SUNLIGHT Trial: Study Design and Outcomes

EP. 5: Factoring in Health-Related Quality of Life Outcomes in mCRC Treatment Selection

EP. 6: Navigating Toxicities: Trifluridine-Tipiracil Plus Bevacizumab

EP. 7: Dosing Trifluridine-Tipiracil (TAS-102) Plus Bevacizumab Considerations: Hepatic or Renal Impairment

EP. 8: Unmet Needs in Third-Line mCRC: Challenges and Opportunities

What are your perspectives regarding the SUNLIGHT trial?
1. Does this trial design with an active-arm comparator arm compared with trials utilizing a placebo-controlled comparator (eg, FRESCO-2, CORRECT) impact or influence your treatment approach? If so, how
Are there certain efficacy outcomes between these agents that have a greater influence or impact on your decision-making?